Elevated levels of thioredoxin 1 in the lungs and sera of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and cryptogenic organizing pneumonia

Internal Medicine

Volumn 49, Issue 22, 2010, Pages 2393-2400

  Iwata, Yasuhiro ^a   Okamoto, Masaki ^a   Hoshino, Tomoaki ^a   Kitasato, Yasuhiko ^a   Sakazaki, Yuki ^a   Tajiri, Morihiro ^a   Matsunaga, Kazuko ^a   Azuma, Koichi ^a   Kawayama, Tomotaka ^a   Kinoshita, Takashi ^a   Imaoka, Haruki ^a   Fujimoto, Kiminori ^a   Kato, Seiya ^b   Yano, Hirohisa ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cryptogenic organizing pneumonia (COP); Idiopathic pulmonary fibrosis (IPF); Non specific interstitial pneumonia (NSIP); Thioredoxin 1

Indexed keywords

CARBON MONOXIDE; LACTATE DEHYDROGENASE; MUCIN 1; THIOREDOXIN 1;

ADULT; AGED; ARTICLE; BRONCHIOLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; METAPLASIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOKING; TISSUE REGENERATION; VITAL CAPACITY;

AGED; CRYPTOGENIC ORGANIZING PNEUMONIA; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PULMONARY FIBROSIS; THIOREDOXINS;

EID: 78549296442     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.4049     Document Type: Article

References (27)

1. Nakamura T, Nakamura H, Hoshino T, Ueda S, Wada H, Yodoi J. Redox regulation of lung inflammation by thioredoxin. Antioxid Redox Signal 7: 60-71, 2005.
2. Hoshino T, Okamoto M, Takei S, Sakazaki Y, Iwanaga T, Aizawa H. Redox-regulated mechanisms in asthma. Antioxid Redox Signal 10: 769-783, 2008.
3. Hoshino T, Nakamura H, Okamoto M, et al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycininduced lung injury. Am J Respir Crit Care Med 168: 1075-1083, 2003.
4. Ichiki H, Hoshino T, Kinoshita T, et al. Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem Biophys Res Commun 334: 1141-1148, 2005.
5. Kinoshita T, Hoshino T, Imaoka H, et al. Thioredoxin prevents the development and progression of elastase-induced emphysema. Biochem Biophys Res Commun 354: 712-719, 2007.
6. Imaoka H, Hoshino T, Takei S, et al. Effects of thioredoxin on established airway remodeling in a chronic antigen exposure asthma model. Biochem Biophys Res Commun 360: 525-530, 2007.
7. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. Embo J 8: 757-764, 1989.
8. Sakuma K, Nakamura H, Nakamura T, et al. Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease.Internal medicine (Tokyo, Japan) 46: 1905-1909, 2007.
9. Callister ME, Burke-Gaffney A, Quinlan GJ, et al. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61: 521-527, 2006.
10. Koura T, Gon Y, Hashimoto S, et al. Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation. Thorax 55: 755-761, 2000.
11. Tiitto L, Kaarteenaho-Wiik R, Sormunen R, et al. Expression of the thioredoxin system in interstitial lung disease. J Pathol 201: 363-370, 2003.
12. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304, 2002.
13. Dina R, Sheppard MN. The histological diagnosis of clinically documented cases of cryptogenic organizing pneumonia: diagnostic features in transbronchial biopsies. Histopathology 23: 541-545, 1993.
14. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 31: 619-625, 2004.
15. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41: 661-670, 2009.
16. Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 148: 637-642, 1993.
17. Kuroki Y, Tsutahara S, Shijubo N, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 147: 723-729, 1993.
18. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152: 1860-1866, 1995.
19. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176: 636-643, 2007.
20. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 177: 433-439, 2008.
21. Imaoka H, Hoshino T, Takei S, et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31: 287-297, 2008.
22. Toda R, Hoshino T, Kawayama T, et al. Validation of "lung age" measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Internal medicine (Tokyo, Japan) 48: 513-521, 2009.
23. Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 278: 3386-3394, 2003.
24. Rahman I, Skwarska E, Henry M, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 27: 60-68, 1999.
25. Lenz AG, Costabel U, Maier KL. Oxidized BAL fluid proteins in patients with interstitial lung diseases. Eur Respir J 9: 307-312, 1996.
26. Hoshino Y, Nakamura T, Sato A, Mishima M, Yodoi J, Nakamura H. Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. Am J Respir Cell Mol Biol 37: 438-446, 2007.
27. Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158: 1680-1684, 1998.